申请人:Ishizuka Natsuki
公开号:US20080103139A1
公开(公告)日:2008-05-01
The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):
wherein R
1
is optionally substituted C1-C8 alkyl and the like; R
2
is C1-C6 alkyl; R
3
is C1-C6 alkyl and the like; or R
2
and R
3
taken together with may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R
4
is hydrogen and the like; G is a group selected from the groups shown by the formula an the like:
wherein R
5
is hydrogen and the like; X
1
is a single bond and the like; X
2
is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of —O—, or —N(R
6
)—, wherein R
6
is hydrogen and the like, and the like; X
3
is a single bond and the like;
a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.
本发明提供了具有激动大麻素受体的作用的化合物,其由式(I)表示:其中,R1是可选取的取代的C1-C8烷基等;R2是C1-C6烷基;R3是C1-C6烷基等;或R2和R3共同形成可选取代的5至10个成员的非芳香碳环;R4是氢等;G是由式等所示的基团中选取的基团:其中,R5是氢等;X1是单键等;X2是可选取代的C1-C8烷基,可以被一或两个-O-或-N(R6)-的基团替代,其中R6是氢等;X3是单键等;其药学上可接受的盐或其溶剂,以及制药组合物、治疗特应性皮炎的制剂和抗瘙痒剂,特别是口服和外用的抗瘙痒剂,每种制剂均以所述化合物为活性成分。